Next Article in Journal
Inconsistent Findings of Cardiac Troponin T and I in Clinical Routine Diagnostics: Factors of Influence
Previous Article in Journal
Impact of Chronic RAAS Use in Elderly COVID-19 Patients: A Retrospective Analysis
Previous Article in Special Issue
Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
jcm-logo
Article Menu
Article

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

1
Myeloid Neoplasms Group, Hematology Department, ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Spain
2
Hematology Department, ICO Hospitalet-Hospital Duran y Reynals, 08908 l’Hospitalet de Llobregat, Spain
3
Hematology Department, ICO Girona-Hospital Josep Trueta, 17007 Girona, Spain
4
Hematology-Oncology Department, Hospital General Universitario Morales Meseguer-CIBERER, UCAM, 30008 Murcia, Spain
5
Hematology Department, Hospital Clínico Universitario-INCLIVA de Valencia, 46010 Valencia, Spain
6
Hematology Department, Hospital Clínico San Carlos (HCSC), Instituto de Medicina de Laboratorio (IML), Instituto de Investigación Sanitaria San Carlos (IdISSC), Department of Medicine, Universidad Complutense de Madrid (UCM), 28040 Madrid, Spain
7
Hematology Department, Hospital General de Granollers, 08402 Granollers, Spain
8
Pharmaceutics Department, ICO Hospitalet-Hospital Duran y Reynals, 08908 l’Hospitalet de Llobregat, Spain
*
Author to whom correspondence should be addressed.
Membership of the Grupo Español de Leucemia Mieloide Crónica (GELMC) is provided in the Acknowledgments.
Academic Editor: Domenico Russo
J. Clin. Med. 2021, 10(14), 3146; https://doi.org/10.3390/jcm10143146
Received: 15 June 2021 / Revised: 12 July 2021 / Accepted: 13 July 2021 / Published: 16 July 2021
(This article belongs to the Special Issue Prognosis and Therapy of Chronic Myeloid Leukemia)
The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response (DMR) and its duration (sDMR), progression rate (CIP), overall survival (OS), and treatment-free remission (TFR) rate. We studied 202 CML patients, 76 expressing the e13a2 and 126 the e14a2, and correlated the differential transcript expression with the above-mentioned parameters. There were no differences in the cumulative incidence of cytogenetic responses nor in the acquisition of DMR and sDMR between the two groups, but the e14a2 transcript had a positive impact on molecular response during the first 6 months, whereas the e13a2 was associated with improved long-term OS. No correlation was observed between the transcript type and TFR rate. View Full-Text
Keywords: chronic myeloid leukemia; BCR-ABL1 transcripts; response to imatinib; survival; discontinuation; relapse-free survival chronic myeloid leukemia; BCR-ABL1 transcripts; response to imatinib; survival; discontinuation; relapse-free survival
Show Figures

Figure 1

MDPI and ACS Style

Marcé, S.; Xicoy, B.; García, O.; Cabezón, M.; Estrada, N.; Vélez, P.; Boqué, C.; Sagüés, M.; Angona, A.; Teruel-Montoya, R.; Ferrer-Marín, F.; Amat, P.; Hernández-Boluda, J.C.; Ibarra, M.M.; Anguita, E.; Cortés, M.; Fernández-Ruiz, A.; Fontanals, S.; Zamora, L.; on behalf of the Grupo Español de Leucemia Mieloide Crónica. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. J. Clin. Med. 2021, 10, 3146. https://doi.org/10.3390/jcm10143146

AMA Style

Marcé S, Xicoy B, García O, Cabezón M, Estrada N, Vélez P, Boqué C, Sagüés M, Angona A, Teruel-Montoya R, Ferrer-Marín F, Amat P, Hernández-Boluda JC, Ibarra MM, Anguita E, Cortés M, Fernández-Ruiz A, Fontanals S, Zamora L, on behalf of the Grupo Español de Leucemia Mieloide Crónica. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. Journal of Clinical Medicine. 2021; 10(14):3146. https://doi.org/10.3390/jcm10143146

Chicago/Turabian Style

Marcé, Sílvia, Blanca Xicoy, Olga García, Marta Cabezón, Natalia Estrada, Patricia Vélez, Concepción Boqué, Miguel Sagüés, Anna Angona, Raúl Teruel-Montoya, Francisca Ferrer-Marín, Paula Amat, Juan C. Hernández-Boluda, Mariana M. Ibarra, Eduardo Anguita, Montserrat Cortés, Andrés Fernández-Ruiz, Sandra Fontanals, Lurdes Zamora, and on behalf of the Grupo Español de Leucemia Mieloide Crónica. 2021. "Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib" Journal of Clinical Medicine 10, no. 14: 3146. https://doi.org/10.3390/jcm10143146

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop